shorters paradise, page-7

Yep we will know in 12 months time. Expect a dividend and revaluation.

Howmany stocks have not had a downward trend over the last twelve months???

Do you see any positives in the Cellestis story or do you not understand the market they are in?

QF is not in the blockbuster pharmaceutical/diagnostic league. It is almost an "orphan" product as its major application is in third world and less affluent regions of the globe. It is therefore more price sensitive and eventhough it is unique and protected by patent Cellestis have got its market position pretty right and also its marketing strategy.

However the market is still very very important and sizeable and has only the old Mantoux test as worn out oposition.

It will be a rare classic success story for an Australian Biotech Diagnostic Company taking a product from Discovery, R&D, Regulatory to Marketing Globally.